Janssen begins Phase III study of diabetes drug canagliflozin

Janssen Research & Development (Janssen) has started a global, multicentre CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial of Invokana (canagliflozin) in patients with type 2 diabetes and d…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news